CNS Platform

CNSAvineuro Pharm. Inc. (USA, http://www.avineuro.com/) and Avineyro Ltd.(Russia, http://ru.avineuro.com/) under licenses of AllaChem are developing a number of drug candidates (AVN 211, AVN 101, AVN-322, etc.) for the treatment of schizophrenia, obesity and Alzheimer’s disease.

We are developing novel molecules with improved pharmacokinetics, efficacy, and safety properties compared to late-stage development compounds. Avineuro’s selective 5-HT6 receptor antagonist drug candidates AVN-211, AVN-322 and multimodal drug candidates AVN-101 and AV3208 are now in clinical and preclinical development for schizophrenia, anxiety Alzheimer’s disease (AD), and obisity. These molecules possess excellent DMPK/tox and behavioral profiles.

CNS